Serina Therapeutics Inc
SER5.165USD
-0.125-2.36%
시장 운영 시간 （ET）시세는 15분 지연됩니다
51.30M시가총액
손실P/E TTM
자세한 내용은 Serina Therapeutics Inc 회사
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
회사 정보
종목 코드 SER
회사 이름Serina Therapeutics Inc
상장일Nov 29, 2018
CEOMr. Steven Ledger
직원 수12
유형Ordinary Share
회계 연도 종료Nov 29
주소601 Genome Way,
도시HUNTSVILLE
증권 거래소NYSE American Consolidated
국가United States of America
우편 번호35806
전화12563279630
웹사이트https://serinatherapeutics.com/
종목 코드 SER
상장일Nov 29, 2018
CEOMr. Steven Ledger
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
수익 분석
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
데이터 없음
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, May 28
마지막 업데이트: Wed, May 28
주주
주주 유형
주주
주주
비율
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
주주
주주
비율
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
주주 유형
주주
비율
Corporation
41.86%
Individual Investor
21.99%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
1.12%
Hedge Fund
1.10%
Research Firm
0.04%
Other
32.76%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
59
6.70M
67.24%
+259.47K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
2023Q1
65
604.47K
56.02%
-8.31K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Juvenescence Ltd
3.27M
32.78%
--
--
Mar 01, 2025
Puffinus L.P.
904.88K
9.08%
--
--
Mar 01, 2025
McMillan (Helen w)
842.40K
8.45%
+133.79K
+18.88%
Mar 01, 2025
Fisk (Barbara M.)
536.28K
5.38%
+33.81K
+6.73%
Mar 01, 2025
Loya (Miguel)
422.10K
4.23%
--
--
Mar 01, 2025
Ledger (Steven A)
323.66K
3.25%
+95.73K
+42.00%
Mar 28, 2025
Broadwood Capital, Inc.
85.22K
0.85%
--
--
Mar 31, 2025
Waverly Advisors, LLC
67.49K
0.68%
--
--
Mar 31, 2025
Bailey (Gregory Hugh)
67.24K
0.67%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
65.33K
0.66%
+3.26K
+5.25%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
날짜
유형
비율
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
